FierceBiotech

March 6, 2015 7:32 PM

3 0

Japanese pharma giant Astellas won FDA approval for an anti-fungal treatment targeting two rare but dangerous infections, the latest drugmaker to take advantage of new incentives for anti-infective products.

Astellas' treatment, to be sold as Cresemba, is an oral and injected solution for invasive aspergillosis and mucormycosis, two infections that commonly afflict patients undergoing chemotherapy or who have received organ transplants. Left untreated, the fungal infections can lead to acute renal failu...

Also read: Iran welcomes OPEC production cut decision

Read more

To category page

Loading...